(CGC) Canopy Growth - Ratings and Ratios

Canopy Growth Corporation (NASDAQ:CGC) is a leading global cannabis company specializing in the production, distribution, and sale of cannabis and hemp-based products for both recreational and medical markets. Operating primarily in the United States, Canada, Germany, and other international markets, the company is divided into three main segments: Canada Cannabis, International Markets Cannabis, and Storz & Bickel. Its product portfolio includes dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles such as gummies, and topical formats, along with vaporizer devices. Products are marketed under a diverse range of brands, including Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana. The company, originally founded as Tweed Marijuana Inc. in 2009, rebranded as Canopy Growth Corporation in September 2015 and is headquartered in Smiths Falls, Canada.

As of the latest data, Canopy Growth Corporation is listed on the NASDAQ under the ticker symbol CGC as a common stock. The company is classified under the Pharmaceuticals sub-industry within the GICS sector. Its current market capitalization stands at approximately $283.39 million USD, with a price-to-book ratio of 0.57 and a price-to-sales ratio of 1.02. The company reports a return on equity of -79.41, reflecting significant profitability challenges. The forward P/E ratio is 0.00, indicating that earnings expectations are not currently factored into the stock price.

3-Month Forecast:

Based on the provided and , the 3-month outlook for Canopy Growth Corporation (NASDAQ:CGC) is as follows:

Price Action: With the last price at $1.40 and declining SMA trends (SMA 20: 1.84, SMA 50: 2.26, SMA 200: 4.96), the stock is expected to face downward pressure. The 20-day average volume of 10,930,705 shares suggests moderate liquidity, but the ATR of 0.18 indicates limited volatility. This could result in a sideways-to-lower trajectory, potentially testing the $1.20-$1.40 range.

Volatility: The ATR of 0.18 signals moderate price fluctuations, with expected intraday and short-term variations remaining constrained. This suggests that the stock may not experience significant breaks above or below its current trading range in the near term.

Fundamental Outlook: The negative return on equity (-79.41) and zero forward P/E ratio highlight ongoing profitability concerns. Without a material improvement in earnings or a strategic restructuring, the stock is likely to remain under pressure. However, the low P/B ratio of 0.57 could attract value investors if the company demonstrates signs of turnaround.